Literature DB >> 12882587

Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.

Richard S Slavik1, Peter J Jewesson.   

Abstract

Some infectious diseases require management with parenteral therapy, although the patient may not need hospitalisation. Consequently, the administration of intravenous antimicrobials in a home or infusion clinic setting has now become commonplace. Outpatient parenteral antimicrobial therapy (OPAT) is considered safe, therapeutically effective and economical. A broad range of infections can be successfully managed with OPAT, although this form of treatment is unnecessary when oral therapy can be used. Many antimicrobials can be employed for OPAT and the choice of agent(s) and regimen should be based upon sound clinical and microbiological evidence. Assessments of cost and convenience should be made subsequent to these primary treatment outcome determinants. When designing an OPAT treatment regimen, the pharmacokinetic and pharmacodynamic characteristics of the individual agents should also be considered. Pharmacokinetics (PK) is the study of the time course of absorption, distribution, metabolism and elimination of drugs (what the body does to the drug). Clinical pharmacokinetic monitoring has been used to overcome the pharmacokinetic variability of antimicrobials and enable individualised dosing regimens that attain desirable antimicrobial serum concentrations. Pharmacodynamics (PD) is the study of the relationship between the serum concentration of a drug and the clinical response observed in a patient (what the drug does to the body). By combining pharmacokinetic properties (peak [C(max)] or trough [C(min)] serum concentrations, half-life, area under the curve) and pharmacodynamic properties (susceptibility results, minimum inhibitory concentrations [MIC] or minimum bactericidal concentrations [MBC], bactericidal or bacteriostatic killing, post-antibiotic effects), unique PK/PD parameters or indices (t > MIC, C(max)/MIC, AUC(24)/MIC) can be defined. Depending on the killing characteristics of a given class of antimicrobials (concentration-dependent or time-dependent), specific PK/PD parameters may predict in vitro bacterial eradication rates and correlate with in vivo microbiologic and clinical cures. An understanding of these principles will enable the clinician to vary dosing schemes and design individualised dosing regimens to achieve optimal PK/PD parameters and potentially improve patient outcomes. This paper will review basic principles of useful PK/PD parameters for various classes of antimicrobials as they may relate to OPAT. In summary, OPAT has become an important treatment option for the management of infectious diseases in the community setting. To optimise treatment course outcomes, pharmacokinetic and pharmacodynamic properties of the individual agents should be carefully considered when designing OPAT treatment regimens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12882587     DOI: 10.2165/00003088-200342090-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  137 in total

Review 1.  What have we learned from pharmacokinetic and pharmacodynamic theories?

Authors:  J J Schentag; K K Gilliland; J A Paladino
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

Review 2.  Economics of home intravenous services.

Authors:  N D Thickson
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

3.  Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.

Authors:  J J Schentag; D E Nix; M H Adelman
Journal:  DICP       Date:  1991-10

Review 4.  Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions.

Authors:  R P Rapp
Journal:  Ann Pharmacother       Date:  1998 Jul-Aug       Impact factor: 3.154

5.  A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses.

Authors:  W J Munckhof; M L Grayson; J D Turnidge
Journal:  J Antimicrob Chemother       Date:  1996-04       Impact factor: 5.790

6.  Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.

Authors:  A Forrest; S Chodosh; M A Amantea; D A Collins; J J Schentag
Journal:  J Antimicrob Chemother       Date:  1997-12       Impact factor: 5.790

7.  Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

Authors:  A S Benko; D M Cappelletty; J A Kruse; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics.

Authors:  J A Paladino; H E Sperry; J M Backes; J A Gelber; D J Serrianne; T J Cumbo; J J Schentag
Journal:  Am J Med       Date:  1991-11       Impact factor: 4.965

Review 9.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

10.  Self-administration of intravenous antibiotics: an efficient, cost-effective home care program.

Authors:  H G Stiver; S K Trosky; D D Cote; J L Oruck
Journal:  Can Med Assoc J       Date:  1982-08-01       Impact factor: 8.262

View more
  10 in total

1.  Effect of delayed pulsed-wave ultrasound on local pharmacokinetics and pharmacodynamics of vancomycin-loaded acrylic bone cement in vivo.

Authors:  Xun-Zi Cai; Shi-Gui Yan; Hao-Bo Wu; Rong-Xin He; Xue-Song Dai; Hai-Xiang Chen; Rui-Jian Yan; Xin-Hua Zhao
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

2.  Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug : as shown by once-daily divalproex-ER.

Authors:  Sandeep Dutta; Ronald C Reed
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 3.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

4.  Limited-sampling strategies for anti-infective agents: systematic review.

Authors:  Denise A Sprague; Mary H H Ensom
Journal:  Can J Hosp Pharm       Date:  2009-09

Review 5.  Treatment of infections caused by multi-resistant microorganisms in hospital at home units.

Authors:  M Mirón-Rubio
Journal:  Rev Esp Quimioter       Date:  2021-09-30       Impact factor: 1.553

6.  Outpatient parenteral antimicrobial therapy (OPAT) in the Republic of Ireland: results of a national survey.

Authors:  E G Muldoon; G M Allison; D Gallagher; D R Snydman; C Bergin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-06-01       Impact factor: 3.267

7.  Are we ready for an outpatient parenteral antimicrobial therapy bundle? A critical appraisal of the evidence.

Authors:  Eavan G Muldoon; David R Snydman; Elizabeth C Penland; Geneve M Allison
Journal:  Clin Infect Dis       Date:  2013-04-09       Impact factor: 9.079

8.  Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection.

Authors:  Jose Luis Lamas Ferreiro; Judith Álvarez Otero; Ana Sanjurjo Rivo; Lucía González González; Irene Rodríguez Conde; María Fernández Soneira; Javier Posada García; Javier de la Fuente Aguado
Journal:  Sci Rep       Date:  2021-04-21       Impact factor: 4.379

9.  Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry.

Authors:  W J Martone; K C Lindfield; D E Katz
Journal:  Int J Clin Pract       Date:  2008-08       Impact factor: 2.503

Review 10.  Managing an outpatient parenteral antibiotic therapy team: challenges and solutions.

Authors:  Jenana Halilovic; Cinda L Christensen; Hien H Nguyen
Journal:  Ther Clin Risk Manag       Date:  2014-06-18       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.